{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T09:24:04Z","timestamp":1781083444735,"version":"3.54.1"},"reference-count":57,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["nmcd-journal.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.numecd.2016.05.006","type":"journal-article","created":{"date-parts":[[2016,5,30]],"date-time":"2016-05-30T22:15:23Z","timestamp":1464646523000},"page":"853-862","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons"],"prefix":"10.1016","volume":"26","author":[{"given":"K.","family":"Yadav","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.C.","family":"Ferdinand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9524","key":"10.1016\/j.numecd.2016.05.006_bib1","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0140-6736(06)68770-9","article-title":"Global burden of disease and risk factors: disease control priorities project. New York, NY","volume":"367","author":"Lopez","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2016.05.006_bib2","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1161\/CIRCULATIONAHA.112.128413","article-title":"Estimating deaths from cardiovascular disease: a review of global methodologies of mortality measurement","volume":"127","author":"Pagidipati","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2016.05.006_bib3","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease meta-analysis of individual data from 27 randomized trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2016.05.006_bib4","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2165\/00129784-200303040-00006","article-title":"Reduction of serum LDL-C levels: a relationship to clinical benefits","volume":"3","author":"LaRosa","year":"2003","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.numecd.2016.05.006_bib5","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/S0735-1097(00)00829-9","article-title":"The aggressive low density lipoprotein lowering controversy","volume":"36","author":"Forrester","year":"2000","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.numecd.2016.05.006_bib6","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/path.4630","article-title":"Local effects of human PCSK 9 on the atherosclerotic lesion","volume":"238","author":"Giunzioni","year":"2016","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.numecd.2016.05.006_bib7","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/ATVBAHA.108.179564","article-title":"The LDL receptor","volume":"29","author":"Goldstein","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.numecd.2016.05.006_bib8","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jacc.2014.03.061","article-title":"Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective15-year outcomes in the Bruneck study","volume":"64","author":"Willeit","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"10.1016\/j.numecd.2016.05.006_bib9","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis society consensus panel statement on assessment, aetiology and management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.numecd.2016.05.006_bib10","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.atherosclerosis.2013.01.023","article-title":"PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells","volume":"227","author":"Levy","year":"2013","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.numecd.2016.05.006_bib11","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hyper cholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.numecd.2016.05.006_bib12","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng1509","article-title":"Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9","volume":"37","author":"Cohen","year":"2005","journal-title":"Nat Genet"},{"issue":"15","key":"10.1016\/j.numecd.2016.05.006_bib13","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1073\/pnas.0501652102","article-title":"Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9","volume":"102","author":"Rashid","year":"2005","journal-title":"Proc Natl Acad Sci U. S. A"},{"key":"10.1016\/j.numecd.2016.05.006_bib14","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.numecd.2016.05.006_bib15","doi-asserted-by":"crossref","first-page":"12882","DOI":"10.1074\/jbc.M110.113035","article-title":"A proprotein convertase subtilisin-like\/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake","volume":"285","author":"Ni","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.numecd.2016.05.006_bib16","doi-asserted-by":"crossref","unstructured":"Chan JC, Piper DE, Cao Q, Liu D, King C, Wang W, et\u00a0al. A proprotein convertase subtilisin\/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. 9820\u20139825, doi: 10.1073\/pnas.0903849106.","DOI":"10.1073\/pnas.0903849106"},{"issue":"3","key":"10.1016\/j.numecd.2016.05.006_bib17","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s10557-015-6588-3","article-title":"PCSK9 inhibition: discovery, current evidence, and potential effects on LDL-C and Lp(a)","volume":"29","author":"Ferdinand","year":"2015","journal-title":"Cardiovasc\u00a0Drugs Ther"},{"key":"10.1016\/j.numecd.2016.05.006_bib18","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/S0140-6736(12)61771-1","article-title":"Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study","volume":"380","author":"Koren","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2016.05.006_bib19","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.112.144055","volume":"126","author":"Raal","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2016.05.006_bib20","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.2012.25790","article-title":"Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial","volume":"308","author":"Sullivan","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.numecd.2016.05.006_bib21","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/S0140-6736(12)61770-X","volume":"380","author":"Giugliano","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2016.05.006_bib22","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/clc.22014","article-title":"Design and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebo- controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy","volume":"35","author":"Kohli","year":"2012","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.numecd.2016.05.006_bib23","unstructured":"Koren MJ, Giugliano RP, Raal FJ, for OSLER Investigators, et\u00a0al."},{"key":"10.1016\/j.numecd.2016.05.006_bib24","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1161\/CIRCULATIONAHA.113.004678","article-title":"Effect of the proprotein convertase subtilisin\/kexin 9 monoclonal antibody, AMG145, in homozygous familial hypercholesterolemia","volume":"128","author":"Stein","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2016.05.006_bib25","unstructured":"http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm455883.htm."},{"key":"10.1016\/j.numecd.2016.05.006_bib26","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1056\/NEJMoa1201832","article-title":"Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia","volume":"367","author":"Roth","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2016.05.006_bib27","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/j.jacc.2012.03.007","article-title":"Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease, SAR236553\/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy","volume":"59","author":"McKenney","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2016.05.006_bib28","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)60771-5","volume":"380","author":"Stein","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2016.05.006_bib29","doi-asserted-by":"crossref","first-page":"A1371","DOI":"10.1016\/S0735-1097(14)61371-1","article-title":"One year open-label treatment with alirocumab 150 mg every two weeks in heterozygous familial hypercholesterolemic patients","volume":"63","author":"Stein","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2016.05.006_bib30","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ijcard.2014.06.049","article-title":"Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized phase 3 trial","volume":"176","author":"Roth","year":"2014","journal-title":"Int J Cardiol"},{"issue":"6","key":"10.1016\/j.numecd.2016.05.006_bib31","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.ahj.2015.03.004","article-title":"Efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study","volume":"169","author":"Kereiakes","year":"2015","journal-title":"Am Heart J"},{"issue":"19","key":"10.1016\/j.numecd.2016.05.006_bib32","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/eurheartj\/ehv028","article-title":"Efficacy and safety of alirocumab in high cardio-vascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial","volume":"36","author":"Cannon","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2016.05.006_bib33","first-page":"211","article-title":"ODYSSEY HIGH FH: efficacy and safety of alirocumab in patients with severe heterozygous familial hypercholesterolemia [abstract]","volume":"130","author":"Ginsberg","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2016.05.006_bib34","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.jacl.2014.09.007","article-title":"Efficacy and safety of alirocumab, a monoclonal antibodytoPCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial","volume":"8","author":"Moriarty","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.numecd.2016.05.006_bib35","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/clc.22327","article-title":"Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20mg): design and rationale of the ODYSSEY OPTIONS studies","volume":"37","author":"Robinson","year":"2014","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.numecd.2016.05.006_bib36","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2016.05.006_bib37","doi-asserted-by":"crossref","first-page":"A1363","DOI":"10.1016\/S0735-1097(15)61363-8","article-title":"Pooled safety and adverse events in nine randomized, placebo-controlled, phase2 and 3 clinical trials of alirocumab [abstract]","volume":"65","author":"Jones","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2016.05.006_bib38","unstructured":"http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm460082.htm."},{"key":"10.1016\/j.numecd.2016.05.006_bib39","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","article-title":"A 52-week placebo-controlled trial of evolocumab in hyper-lipidemia","volume":"370","author":"Blom","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2016.05.006_bib40","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","article-title":"Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab","volume":"63","author":"Koren","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2016.05.006_bib41","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","article-title":"Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo- controlled phase 3 clinical trial of evolocumab","volume":"63","author":"Stroes","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2016.05.006_bib42","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1001\/jama.2014.4030","article-title":"Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial","volume":"311","author":"Robinson","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.numecd.2016.05.006_bib43","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2016.05.006_bib44","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2016.05.006_bib45","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2016.05.006_bib46","doi-asserted-by":"crossref","first-page":"A1351","DOI":"10.1016\/S0735-1097(15)61351-1","article-title":"A comprehensive safety analysis of 6026 patients from phase 2 and 3 short and long term clinical trials with evolocumab (AMG 145) [abstract]","volume":"65","author":"Toth","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2016.05.006_bib47","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.amjcard.2015.02.006","article-title":"Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin\/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia","volume":"115","author":"Ballantyne","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.numecd.2016.05.006_bib48","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3389\/fgene.2015.00136","article-title":"PCSK9 variation and association with blood pressure in African Americans: preliminary findings from the HyperGEN and REGARDS studies","volume":"6","author":"Tran","year":"2015","journal-title":"Front Genet"},{"key":"10.1016\/j.numecd.2016.05.006_bib50","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.numecd.2014.05.009","article-title":"Resistance and intolerance to statins","volume":"24","author":"Reiner","year":"2014","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"10","key":"10.1016\/j.numecd.2016.05.006_bib51","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1517\/17425255.2015.1075506","article-title":"PCSK9 inhibitors \u2013 past, present and future","volume":"11","author":"Reiner","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.numecd.2016.05.006_bib52","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/nrcardio.2015.92","article-title":"Management of patients with familial hypercholesterolaemia","volume":"12","author":"Reiner","year":"2015","journal-title":"Nat Rev Card"},{"issue":"12","key":"10.1016\/j.numecd.2016.05.006_bib53","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1177\/1060028015608487","article-title":"Therapeutic potential and critical analysis of the PCSK9 monoclonal antibodies evolocumab and alirocumab","volume":"49","author":"White","year":"2015","journal-title":"Ann Pharmacother"},{"issue":"12","key":"10.1016\/j.numecd.2016.05.006_bib54","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/phar.1672","article-title":"Therapeutic management of familial hypercholesterolemia: current and emerging drug therapies","volume":"35","author":"Patel","year":"2015","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.numecd.2016.05.006_bib55","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.phrs.2015.09.021","article-title":"Ciccone MM focus on alirocumab: a PCSK9 antibody to treat hypercholesterolemia","volume":"102","author":"Devito","year":"2015","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.numecd.2016.05.006_bib56","doi-asserted-by":"crossref","first-page":"8279","DOI":"10.1074\/jbc.M112.421370","article-title":"Low density lipoprotein binds to proprotein convertase subtilisin\/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation","volume":"288","author":"Kosenko","year":"2013","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.numecd.2016.05.006_bib57","doi-asserted-by":"crossref","first-page":"E41","DOI":"10.1210\/jc.2014-3066","article-title":"Removal of plasma mature and furin-cleaved proprotein convertase subtilisin\/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9","volume":"100","author":"Hori","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2016.05.006_bib58","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1161\/CIRCRESAHA.113.302655","article-title":"Loss of plasma proprotein convertase subtilisin\/kexin 9 (PCSK9) after lipoprotein apheresis","volume":"113","author":"Tavori","year":"2013","journal-title":"Circ Res"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475316300655?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475316300655?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T11:20:43Z","timestamp":1536664843000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475316300655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":57,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S0939475316300655"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2016.05.006","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2016.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}